Skip to main content
. 2021 May 1;24(5):102457. doi: 10.1016/j.isci.2021.102457

Figure 3.

Figure 3

Loss of TSPO inhibited ACAT2 independent of cholesterol accumulation and TSPO-ACAT2 interacted in MAMs

(A) CEH immunoblots from DMSO-, AcLDL-, and AcLDL+58035-treated Scram and TSPO KD Huh7 cells. The numbers under the lanes represent the CEH/GAPDH.

(B) ACAT2 immunoblot from DMSO-, AcLDL-, and AcLDL+58035-treated Scram and TSPO KD Huh7 cells. The bar graph is the fold change of ACAT2/GAPDH.

(C) Immunofluorescence staining of ACAT2 (green) in DMSO-, AcLDL-, and AcLDL+58035-treated Scram and TSPO KD Huh7 cells. Scale, 10 μm.

(D) CEH immunoblot from DMSO-, AcLDL-, and AcLDL+58035-treated WT and TSPO KO primary mouse hepatocytes. The numbers under the lanes represent the CEH/GAPDH.

(E) ACAT2 immunoblot from DMSO-, AcLDL-, and AcLDL+58035-treated WT, TSPO KO primary mouse hepatocytes. The bar graph is the fold change of ACAT2/GAPDH.

(F) Immunofluorescence staining of ACAT2 (green) in DMSO-, AcLDL-, and AcLDL+58035-treated WT and TSPO KO primary mouse hepatocytes Scale, 10μm.

(G) Coimmunoprecipitation of ACAT2-Turbo-GFP and TSPO-Myc and immunoblot with Anti-GFP or Anti-C-Myc in Huh7 cells.

(H) PLA of ACAT2 and TSPO interactions (red spot) in Huh7 cells. Scale, 10 μm. Data are represented as mean ± SD, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 by Student's t-test.